>>>CytoDyn Inc. (CytoDyn), a late-stage biotechnology company, announced today that it is currently accepting only 155 more candidates across the country for its Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19.>>>

I like the way the author phrases his thinking. This is a public notice that there are only only 155 slots left in this trial. If your doc waits too long your SOL.